Morgan Stanley Starts Infinity Pharmaceutical (INFI) at Overweight
Tweet
Share
E-mailGet Alerts INFI Hot Sheet
Price: $0.04 --0%
Rating Summary:
12 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Rating Summary:
12 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Join SI Premium – FREE
Morgan Stanley initiated coverage on Infinity Pharmaceutical (NASDAQ: INFI) with an Overweight rating and a price target of $17.00.
For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.
Shares of Infinity Pharmaceutical closed at $11.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Assumes Harley-Davidson (HOG) at Overweight, 'Freshly Tuned Up with Open Road Ahead'
- UBS Starts Hutchmed China Ltd (13:HK) at Buy
- JPMorgan Starts China Merchants Energy Shipping Co Ltd (601872:CH) at Overweight
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
